ArticleCureus2026
Cell-Type-Specific Transcriptomic Alterations in the Epileptic Prefrontal Cortex and Complementary Neuroimaging Findings in an Independent Cohort.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesEpilepsy is a complex neurological disorder involving distributed neuronal and glial networks. The cellular transcriptional states associated with epilepsy and their relationship to macroscopic brain abnormalities remain incompletely characterized. We therefore performed a two-part exploratory study using a public postmortem prefrontal cortex (PFC) single-nucleus RNA sequencing (snRNA-seq) dataset and an independent clinical neuroimaging cohort.
methodsPublic snRNA-seq data from eight individuals classified as having epilepsy and seven controls were processed with CellRanger (10x Genomics, Pleasanton, California) and Seurat (Satija Lab, New York Genome Center, New York, New York). Cell-type composition, exploratory nucleus-level differential expression, Gene Ontology (GO)/Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment, Monocle pseudotime analysis, and SCENIC (Single-Cell rEgulatory Network Inference and Clustering) regulon inference were evaluated. Separately, 18F-fluorodeoxyglucose positron emission tomography-computed tomography (18F-FDG PET-CT) and diffusion tensor imaging (DTI) data from 16 patients with neocortical epilepsy were analyzed using within-patient lesion-versus-contralateral comparisons. Because the sequencing and imaging cohorts were independent, the two components were interpreted as complementary observations rather than direct cross-modal validation.
resultsAfter quality control, 16,132 nuclei were retained (11,587 control and 4,545 epilepsy nuclei). Oligodendrocyte-lineage representation was lower in epilepsy than in controls (5.3% vs. 14.7%; exploratory P = 0.023), whereas layer 2/3 (L2/3) excitatory neurons showed higher representation (47.7% vs. 29.5%). Exploratory cell-level enrichment analysis identified MAPK-related signaling as the top-ranked KEGG pathway among upregulated genes in L2/3 neurons, and SCENIC identified a STAT3 (signal transducer and activator of transcription 3)-associated reactive astrocytic regulon pattern. Oligodendrocyte-lineage nuclei showed altered gene-expression patterns and different distributions along an inferred pseudotime continuum; these observations were not interpreted as direct evidence of impaired differentiation. In the independent imaging cohort, PET signal was lower in epileptic lesions than in contralateral regions (P = 0.007), and fractional anisotropy (FA) was reduced (P < 0.001), whereas mean diffusivity (MD) was not significantly different (P = 0.101). PET and FA findings remained significant after Bonferroni correction for three prespecified imaging comparisons (adjusted threshold P < 0.0167).
conclusionsThe study identifies exploratory cell-type-specific transcriptional alterations in the public PFC dataset and, independently, metabolic and white matter microstructural abnormalities in a separate neocortical epilepsy cohort. These findings represent complementary observations across different biological scales rather than direct molecular-imaging validation. Larger donor-level transcriptomic studies, matched molecular-imaging cohorts, and functional experiments are required to validate the candidate cellular and molecular signatures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.